Description
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon3.,
Disease:Carcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-CEACAM1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CEACAM1 also known as CD66a is a cell adhesion molecule that plays a critical role in various cellular processes. The protein weighs around 120 kDa and is part of the immunoglobulin superfamily. CEACAM1 is expressed on the surface of various cell types including epithelial cells leukocytes and endothelial cells. The presence of CEACAM1 is important in tissues such as the liver lungs and gastrointestinal tract where it performs essential roles in cell signaling and communication.
Biological function summary
CEACAM1 influences cellular adhesion and immune responses by mediating cell-cell interactions. It forms homophilic dimers at the cell surface and it can participate in heterophilic interactions with other proteins making it part of complex cell signaling networks. These interactions regulate immune cell functions contributing to innate immune responses and cellular homeostasis. CEACAM1 also modulates angiogenesis endothelial cell permeability and apoptosis.
Pathways
CEACAM1 is involved in signaling and regulatory pathways important for immune surveillance and inflammation. It is a part of the TGF-beta signaling pathway affecting cellular proliferation and differentiation. CEACAM1 interacts with proteins such as SHP-1 and SHP-2 which are essential in modulating immune responses. Additionally CEACAM1 influences the MAPK/ERK pathway which plays a role in cell growth and survival.
CEACAM1 is associated with cancer and inflammatory diseases. In colorectal cancer altered expression of CEACAM1 contributes to tumor progression and metastasis. The protein also plays a role in inflammatory bowel disease where it affects the epithelial barrier function and immune cell interaction. Through these conditions CEACAM1 interacts with other proteins like CEA and IL-6 which are pivotal in disease development and progression.
